ArticleThe American journal of pathology2012
Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes.
Article in The American journal of pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 65 citations in OpenAlex.
- Complement activation and fibrinolysis dysregulation drive contrast-induced acute kidney injury: a 4D proteomics rat study.Renal failure · 2026Article
- Pharmacological Blockade of LPAR1 Does Not Provide Neuroprotection in a Rat Model of Ocular Hypertensive Glaucoma.Translational vision science & technology · 2026Article
- Unraveling the Role of Autotaxin and Lysophosphatidic Acid in Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Potential.International journal of molecular sciences · 2025Review
- Comparative Analysis of Lysophosphatidic Acid Levels in Fibromyalgia and Other Painful Conditions in Female Patients.European journal of pain (London, England) · 2025Article
- Making a difference.European journal of translational myology · 2024Article
- Construction of a Searchable Database for Gene Expression Changes in Spinal Cord Injury Experiments.Journal of neurotrauma · 2024Article
- Astrocytic Neuroimmunological Roles Interacting with Microglial Cells in Neurodegenerative Diseases.International journal of molecular sciences · 2023Review
- Review
- The LPA-CDK5-tau pathway mediates neuronal injury in an in vitro model of ischemia-reperfusion insult.BMC neurology · 2022Article
- Critical Roles of Lysophospholipid Receptors in Activation of Neuroglia and Their Neuroinflammatory Responses.International journal of molecular sciences · 2021Review
- Lysophosphatidic acid (LPA)-antibody (504B3) engagement detected by interferometry identifies off-target binding.Lipids in health and disease · 2021Article
- CRISPR gRNA phenotypic screening in zebrafish reveals pro-regenerative genes in spinal cord injury.PLoS genetics · 2021Article
- Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies.Signal transduction and targeted therapy · 2021Review
- Dual Role of Lysophosphatidic Acid Receptor 2 (LPAFrontiers in cellular neuroscience · 2021Article
- Antibodies Against Lysophosphatidic Acid Protect Against Blast-Induced Ocular Injuries.Frontiers in neurology · 2020Article
- Strategies for Oligodendrocyte and Myelin Repair in Traumatic CNS Injury.Frontiers in cellular neuroscience · 2020Review
- Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases.Molecular neurobiology · 2020Review
- Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis.European heart journal · 2019Article
- Lysophosphatidic acid receptor type 2 activation contributes to secondary damage after spinal cord injury in mice.Brain, behavior, and immunity · 2019Article
- CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia.Journal of pain research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
Evidence suggests a proinflammatory role of lysophosphatidic acid (LPA) in various pathologic abnormalities, including in the central nervous system. Herein, we describe LPA as an important mediator of inflammation after spinal cord injury (SCI) in zebrafish and mice. Furthermore, we describe a novel monoclonal blocking antibody raised against LPA that potently inhibits LPA's effect in vitro and in vivo. This antibody, B3, specifically binds LPA, prevents it from interacting with its complement of receptors, and blocks LPA's effects on the neuronal differentiation of human neural stem/progenitor cells, demonstrating its specificity toward LPA signaling. When administered systemically to mice subjected to SCI, B3 substantially reduced glial inflammation and neuronal death. B3-treated animals demonstrated significantly more neuronal survival upstream of the lesion site, with some functional improvement. This study describes the use of anti-LPA monoclonal antibody as a novel therapeutic approach for the treatment of SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.